Chemoradiation for Oesophageal Cancer
Author Information
Author(s): van Meerten E, Muller K, Tilanus H W, Siersema P D, Eijkenboom W M H, van Dekken H, Tran T C K, van der Gaast A
Primary Institution: Erasmus MC - University Medical Centre Rotterdam, The Netherlands
Hypothesis
The study aims to assess the efficacy and safety of preoperative chemoradiation with carboplatin and paclitaxel for patients with resectable oesophageal cancer.
Conclusion
Weekly neoadjuvant paclitaxel and carboplatin with concurrent radiotherapy is well tolerated and achieves a high rate of radical resections.
Supporting Evidence
- All 54 entered patients completed the chemoradiation without delay or dose-reduction.
- 63% had a major endoscopical response after treatment.
- Postoperative mortality rate was 7.7% with a 100% radical resection rate.
Takeaway
This study tested a new treatment for patients with oesophageal cancer and found it to be safe and effective, helping many patients have successful surgeries.
Methodology
Patients received weekly paclitaxel and carboplatin with concurrent radiotherapy followed by surgery.
Potential Biases
The study may have selection bias due to its phase II design.
Limitations
The study is a phase II trial, which may carry risks of selection bias.
Participant Demographics
91% male, 76% had adenocarcinoma, median age 59 years.
Statistical Information
Confidence Interval
95% CI 0–15%
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website